Articles tagged with Breast Cancer
Patients with breast cancer in conflict zones face significant barriers to treatment, including lack of standard procedures and funding for rebuilding capacity. This results in many patients being diagnosed with advanced breast cancer, often with limited palliative care options.
Researchers at IRB Barcelona have identified the mechanism by which the MAF protein promotes breast cancer metastasis, revealing a key interaction with the estrogen receptor. This finding opens up new therapeutic options for patients with high MAF levels, who may benefit from treatments aimed at preventing metastases.
The PhRMA Foundation awarded two $500,000 Frontier Awards to researchers William Padula and Surachat Ngorsuraches for their patient-centered value assessment models. Their studies will advance the field of value assessment by applying theoretical models in a real-world context and engaging with patients to ensure their voices are inclu...
Researchers discovered narrow-spectrum Wnt signaling inhibitors can suppress breast cancer tumors and reduce chemo-resistant cells in mice. The treatment, derived from a bacterial toxin, targets specific receptors to minimize bone density side effects.
Scientists at Nagoya University have discovered a reliable cancer marker, stromal cell-derived factor 4 (SDF-4), that detects gastric cancer with high accuracy. The protein is found in high levels even in patients with stage I gastric cancer, suggesting its potential for early detection.
Researchers found that breast cancer cells rely on vitamin B5 to grow and survive. In a study published in Nature Metabolism, scientists discovered that limiting vitamin B5 intake slowed the growth of breast cancer tumours in mice.
Researchers have found that simultaneously inhibiting two proteins, LOXL2 and BRD4, can help slow the growth of triple-negative breast cancer cells. This 'double strike' strategy shows promise in improving the prognosis of this aggressive disease, which is resistant to existing treatments.
A study finds that people with advanced breast cancer are more likely to stop working, leading to significant economic losses. The research estimates a loss of €28,676,754 in productivity over three years in Portugal.
Patients with HER2-positive breast cancer that has spread to other parts of the body survive for longer if treated with pyrotinib. The new drug targets proteins involved in HER2-positive breast cancer and shows a 22% reduction in risk of death compared to lapatinib.
Researchers at the University of Leicester have received a significant financial boost to advance their cancer treatment research. The team will investigate 'liquid biopsies' to reveal vital clues about cancer genetic makeup, aiming to predict how cancer changes and which treatment works best for individual patients.
New research suggests that vitamin D supplements can reduce the risk of peripheral neuropathy in patients undergoing paclitaxel treatment. The study found that patients with vitamin D deficiency were more likely to experience severe neuropathy, and that inducing vitamin D deficiency caused similar symptoms in a mice model study.
A study published in Oncotarget reveals that HER2 mutant alleles play a crucial role in determining treatment response to neratinib and poziotinib. Researchers found that individual HER2 mutant alleles have distinct effects on therapeutic efficacy, suggesting new targets for breast cancer therapy.
A study of 185 women found that high neighborhood deprivation was associated with changes in DNA methylation and gene expression in Black women with breast cancer. This suggests a potential link between environmental factors and biological susceptibility to chronic diseases.
Researchers use 3D human breast organoids to study cellular and molecular processes of lactogenesis, milk production, and involution. The models form structures characteristic of human breast tissue, maintain various cell subtypes, and respond to hormone or drug treatments.
Researchers at MUSC Hollings Cancer Center have identified new targets for treating breast cancer that has become resistant to hormone therapy and CDK4/6 inhibitors. By understanding the molecular mechanisms of resistance, the team has found potential solutions using epidermal growth factor receptors and PARP inhibitors.
A recent study published in JAMA Oncology found that false-positive mammography results may significantly increase the risk of developing breast cancer. The risk varies depending on individual characteristics and follow-up, highlighting the need for personalized screening strategies after a false-positive result.
Mutations in the PIK3CA gene lead to elevated production of the PI3Ka protein, found in approximately 40% of hormone receptor-positive breast cancers. Next-generation PI3Kalpha inhibitors targeting a different region of the mutant protein show promise in overcoming resistance.
Researchers found a significant long-term increased risk of breast cancer among women with false-positive mammography results. The risk is highest in women aged 60-75 and those with low breast density, facing a 60% increased risk over the subsequent 20 years.
A successful approach that eliminated Delaware's racial disparities in colorectal cancer can now be applied to breast cancer. The 'village' model focuses on building community partnerships and increasing access to care to reduce disparities.
Researchers found that FAAH inhibition reduced breast cancer growth in immunodeficient mice and induced apoptosis of breast cancer cells. The combination of FAAH inhibitors and endocannabinoids was the most effective treatment approach.
A new study by NUS provides insights into how BRCA2 mutations impact breast tissue cells, leading to early breast cancer development. The research found that healthy mammary glands are not predisposed to form lesions, but HR- luminal cells with BRCA2 mutations exhibit enhanced organoid formation and survival under replication stress.
Researchers at the University of Cincinnati Cancer Center found that SmartClips, a wireless localization method for breast tumors, is safe and effective. The devices reduce patient discomfort and improve surgery efficiency by allowing surgeons to locate tumors more accurately.
Researchers have found that targeting protein eIF4A with the small molecule drug Zotatifin can suppress tumor cell proliferation and remodel the immune microenvironment in triple-negative breast cancer. The promising findings support pursuing clinical trials to assess the potential patient benefits of this approach.
A new antibody created by Cold Spring Harbor Laboratory researchers may offer an effective treatment for some breast cancers. The antibody targets the PTPRD enzyme, which is overabundant in certain breast cancers and helps them spread.
The TMIST breast cancer screening trial is expanding to Thailand, aiming to improve outcomes for Black and Hispanic women. The trial, led by the ECOG-ACRIN Cancer Research Group, is comparing 3-D and 2-D mammography in 128,905 women to better inform tailored future screenings.
Researchers have discovered that a motor protein called dynein powers the movement of breast cancer cells in soft tissue models, offering a potential target for treatment. This finding could fundamentally change how cancer is treated by paralyzing cancer cells rather than killing them.
Researchers found that an adaptive memory tracking training program can improve cognitive function, particularly attention and working memory, in women treated for breast cancer. The training showed lasting gains after just 12 hours of practice.
A study of 9,479 participants identified racial and ethnic disparities in breast cancer survival, highlighting the need for targeted interventions to improve outcomes for at-risk subgroups. The findings suggest that focused care approaches can address these disparities and promote more equitable treatment.
Researchers have discovered that genetic ancestry influences the biology of normal breast tissue and how it factors into the development of aggressive breast cancers. PZP cells, naturally higher in Black women, can influence cancer cell behavior and growth.
The partnership aims to reduce disparities in cancer research and drug development through collaborations, resources, and training programs. Key projects will focus on breast and pancreatic cancers, particularly luminal B breast cancers disproportionately affecting women of African descent.
A research team from the University of California - Davis Health has identified a crucial epitope on the CD95 receptor that can trigger programmed cell death in cancer cells. This finding could lead to improved cancer treatments and potentially enhance CAR T-cell therapy for solid tumors like ovarian cancer.
Researchers at Penn Medicine have received a $10 million grant to develop a new strategy for preventing breast cancer recurrence by targeting dormant tumor cells. In a phase II clinical trial, the team successfully cleared dormant cells from over 80% of patients, offering a promising proof-of-concept for this approach.
Researchers found that online educational materials about breast surgery have a negative tone, exceed recommended reading levels, and are of poor quality. Studies assessed readability, bias, quality, and tone using validated tools, highlighting the need for accessible materials.
A new AI-based tool estimates patient-specific cancer survival rates using machine learning, offering personalized prognosis for patients with breast, thyroid, and pancreatic cancers. The Cancer Survival Calculator differs from existing estimators by incorporating multiple factors beyond disease stage.
A new cancer immunotherapy that targets two immune-evading tumor tactics has shown promising results in an early clinical trial. The drug, tebotelimab, blocks both PD-1 and LAG-3 proteins, leading to a double-digit response rate in patients with advanced solid tumors or blood cancers.
Researchers found that polygenic risk scores identify only 11% of individuals who develop disease and generate 5% false positives. The scores contribute little health benefit while adding cost and complexity to healthcare systems.
A team of researchers aims to develop drug therapies by targeting genes that affect metabolism in people with Down syndrome, potentially improving their quality of life. The project will focus on the protein SIM2, which has been linked to breast cancer and metabolic changes in individuals with the condition.
Researchers will study the impact of exercise, intermittent fasting, and their combination on fatigue, biomarkers of inflammation, and quality of life in women with advanced breast cancer. The trial aims to improve treatment tolerability and possibly life duration for these patients.
A team of researchers has developed a new visualization tool combining high-speed cameras and fluorescent injection to distinguish tumor tissue from normal tissue across cancer types. The technique, known as fluorescence lifetime (FLT) imaging, achieved an accuracy of over 97% in distinguishing tumor tissue from healthy tissue.
Researchers created a 3D printed tumor model using bioprinting and synthetic chips to better understand complex cancers. The model simulates the surrounding environment, addressing limitations of traditional 2D models.
Researchers developed a nanocapsule that reduces lactate levels and releases hydrogen peroxide, recruiting and activating immune cells to attack tumors. The approach increased immune cell activity by 2-5-fold, improving cancer immunotherapy success rates.
A University of Massachusetts Amherst team demonstrates a protein antigen from a childhood vaccine can be delivered into malignant tumor cells to refocus the immune system against cancer. The bacteria-based intracellular delivering system shows promise in treating pancreatic, liver, and metastatic breast tumors.
A multilevel primary care intervention, including electronic health record reminders and patient outreach, improved timely follow-up of overdue abnormal cancer screening test results for breast, cervical, colorectal, and lung cancer. The intervention was found to be effective in reducing missed screenings.
Researchers have pinpointed the molecular mechanism by which a large portion of BRCA1 mutations cause cancers in women. The study found that the E3 ligase activity of BRCA1 is crucial in several stages of DNA repair and tumor suppression, reinterpreting previous findings.
A recent study by UTHealth Houston found that the offspring of adolescent and young adult women with a history of cancer face a higher risk of birth defects. The study examined 6,882 offspring ages 12 months and younger and found an increased risk of specific types of defects in the offspring of women with a history of cancer.
Researchers discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs), with encouraging results from phase II basket studies demonstrating activity in platinum-sensitive relapsed SCLC and other malignancies. Lurbinectedin's mechanism of action involves inhibiting oncogenic transcription, promoting apoptosis and cell death.
The study analyzed 10,000 gene expression signatures to assess their prognostic ability, finding that they lead to accurate patient prognosis in no more than 80% of cases. The researchers emphasize the need for a comprehensive approach incorporating molecular, clinical, histological, and other factors to ensure an accurate prognosis.
A new study by Columbia University Mailman School of Public Health found that women living in more walkable neighborhoods have a lower risk of obesity-related cancers, particularly postmenopausal breast cancer. Neighborhood walkability is associated with increased physical activity and reduced car-dependency.
Researchers discovered NKG2A receptors as potential targets to overcome immunotherapy resistance in breast cancer, offering a promising approach for treating immunotherapy-resistant triple-negative breast cancer patients.
Researchers at MedUni Vienna discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of P-glycoprotein, opening new possibilities for delaying relapse. This breakthrough could represent a step forward in treating aggressive triple-negative breast cancer, which has limited treatment options and ...
A randomized study shows that shorter radiation therapy courses are just as effective in preventing cancer return and reducing side effects for patients with breast reconstruction. The accelerated treatment regimen saved patients time, money, and experienced fewer treatment breaks.
Researchers found a shorter course of radiation therapy provides equivalent protection against breast cancer recurrence and physical side-effects, but reduces life disruption and financial burden. Patients reported less burden on their time and finances, with improved quality of life.
Researchers have made significant progress in using immunotherapies prior to surgery, leading to better biomarkers and more effective combination therapies. This approach has shown promise in various cancer types, including lung cancer, triple-negative breast cancer, melanoma, and gastrointestinal cancers.
Cancer cells exploit enhancer DNA to accelerate tumor growth, according to researchers at the University of Toronto. The study found that specific proteins regulate this process, suggesting potential treatments through FOXA1 or NFIB suppression.
A new poll found that 62% of people aged 50-80 disagree with using life expectancy as a factor in determining cancer screening guidelines. The majority also believes that some older adults should still receive cancer screenings even if guidelines don't recommend them.
A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to HER2-targeted treatment in HER2-positive metastatic breast cancer patients. Whole-body PET/CT enables quantification of HER2 expression and predicts metabolic response, potentially sparing patients from unnecessary side effects.
A new report highlights the significant impact of gender inequality on women's experiences with cancer, including unequal access to prevention, diagnosis, and treatment. The Commission calls for a more inclusive and responsive health system to address these disparities.
Researchers found that adding dendritic cell boosting therapy to radiation and CTLA4 inhibitor combination produced synergistic effect, eliciting tumor regression. This approach resulted in complete or almost complete elimination of targeted tumors.
A new clinical and research partnership has created an AI model that can predict whether cancerous tissue has been fully removed from the body during breast cancer surgery. The model performed as well as humans in identifying positive margins, especially in patients with higher breast density.
A study found that 80.3% of patients with metastatic breast cancer who received standard care treatment with alpelisib developed hyperglycemia, with 40.2% experiencing serious hyperglycemia. Lifestyle interventions and medication may help improve blood sugar levels and reduce the risk of needing to discontinue the drug.